Echocardiography

Visura Technologies Presents TEECAD Real-World Clinical Data at ASE 2023

Retrieved on: 
Tuesday, June 20, 2023

MINNEAPOLIS, June 20, 2023 /PRNewswire/ -- Visura Technologies, Inc., a privately-held medical device company dedicated to delivering state-of-the-art visualization solutions to improve the safety and success of transesophageal echocardiogram (TEE) probe intubations, announced today it will be attending the American Society of Echocardiography's (ASE) 34th Annual Scientific Sessions in Baltimore, MD June 23-26. At this year's meeting, the TEECAD system will be highlighted in an abstract poster presentation by Sunil Mankad MD, Professor of Medicine, and Director of Transesophageal Echocardiography at the Mayo Clinic in Rochester, MN on Sunday, June 25 at 2:00 pm. In addition, Visura will release a new 15 patient TEECAD white paper from a world-renowned heart center.

Key Points: 
  • In addition, Visura will release a new 15 patient TEECAD white paper from a world-renowned heart center.
  • "The presentation of the clinical data from Mayo Clinic is an important milestone for Visura and real-time visualization for TEE procedures," said David Marmor, Cardiologist at Shaare Zedek Medical Center in Jerusalem, Israel and Founder of Visura Technologies.
  • Clinical data continues to support the need for sighted-TEE intubation to reduce TEE-related complications and increase first pass intubation success.
  • Visit Visura and the TEECAD Innovation Station at ASE booth 513 to learn more.

Aviv Clinics Spotlights New Hyperbaric Oxygen Therapy Study Sharing Its Effect on Myocardial Function in Post-COVID-19 Patients

Retrieved on: 
Tuesday, June 13, 2023

The study, The Effect of Hyperbaric Oxygen Therapy on Myocardial Function in Post-COVID-19 Syndrome Patients: a randomized controlled trial , was conducted by Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center and Tel Aviv University, and published in Scientific reports.

Key Points: 
  • The study, The Effect of Hyperbaric Oxygen Therapy on Myocardial Function in Post-COVID-19 Syndrome Patients: a randomized controlled trial , was conducted by Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center and Tel Aviv University, and published in Scientific reports.
  • The study evaluated the effect of HBOT on the cardiac function of post-COVID-19 patients with ongoing symptoms for at least three months after a COVID-19 diagnosis, i.e.
  • In this randomized controlled trial, 60 patients were randomized to one of the two study arms— the sham-controlled group and the HBOT group.
  • Aviv Clinics offers an advanced, comprehensive treatment program, the Aviv Medical Program, tailored to the needs of each patient.

The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)

Retrieved on: 
Thursday, May 11, 2023

Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.

Key Points: 
  • Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.
  • With the CV-dedicated configuration, Esaote offers best-in-class diagnostic capability and high-level flexibility to cardiologists and mobile service professionals, anytime and anywhere.
  • Leader in the biomedical equipment sector (ultrasound, magnetic resonance imaging, software for managing the diagnostic process).
  • At the end of 2022, the Group had 1,250 employees, with more than half of them in Italy.

The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)

Retrieved on: 
Thursday, May 11, 2023

Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.

Key Points: 
  • Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.
  • With the CV-dedicated configuration, Esaote offers best-in-class diagnostic capability and high-level flexibility to cardiologists and mobile service professionals, anytime and anywhere.
  • Leader in the biomedical equipment sector (ultrasound, magnetic resonance imaging, software for managing the diagnostic process).
  • At the end of 2022, the Group had 1,250 employees, with more than half of them in Italy.

BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Wednesday, May 10, 2023

SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission.

Key Points: 
  • SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission.
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights.
  • In March, positive echocardiography data from the trial was presented at the 2023 American College of Cardiology annual meeting in New Orleans.
  • First Quarter 2023 Financial Results:
    Revenues were approximately $64 thousand for the three months ended March 2023, compared to approximately $60 thousand for the three months ended March 2022.

Babyscripts Welcomes New Executive VP of Revenue Andrew Reeve

Retrieved on: 
Wednesday, May 3, 2023

WASHINGTON, May 3, 2023 /PRNewswire-PRWeb/ -- Babyscripts, the leading virtual care platform for managing obstetrics, today announced the appointment of Andrew Reeve as Executive Vice President of Revenue. In this role, Mr. Reeve will be responsible for accelerating Babyscripts' strategic partnerships in payer and provider markets. Andrew will lead Babyscripts' go-to-market strategy and functions driving market share, revenue growth, and customer engagement.

Key Points: 
  • WASHINGTON, May 3, 2023 /PRNewswire-PRWeb/ -- Babyscripts , the leading virtual care platform for managing obstetrics, today announced the appointment of Andrew Reeve as Executive Vice President of Revenue.
  • In this role, Mr. Reeve will be responsible for accelerating Babyscripts' strategic partnerships in payer and provider markets.
  • Andrew will lead Babyscripts' go-to-market strategy and functions driving market share, revenue growth, and customer engagement.
  • Before joining Babyscripts, Andrew held the position of Chief Revenue Officer at Ultromics, an Oxford University spin-out focused on applying artificial intelligence to echocardiography for improved detection and risk-stratification of cardiovascular disease.

The innovative echocardiography software platform "CAAS Qardia" by Pie Medical Imaging receives medical device certification in Japan

Retrieved on: 
Monday, April 24, 2023

MAASTRICHT, Netherlands, April 24, 2023 /PRNewswire/ -- Pie Medical Imaging, a global leader in cardiac imaging, announced it has received NINSHO Medical Device Certification for CAAS Qardia, their innovative echocardiography software platform.

Key Points: 
  • MAASTRICHT, Netherlands, April 24, 2023 /PRNewswire/ -- Pie Medical Imaging, a global leader in cardiac imaging, announced it has received NINSHO Medical Device Certification for CAAS Qardia, their innovative echocardiography software platform.
  • CAAS Qardia excels at myocardial strain analysis, stress-echo, diastolic function assessment, and (PISA) valve analysis.
  • René Guillaume, Managing Director of Pie Medical Imaging said: "With this certification of CAAS Qardia, an easy-to-use and accurate tool becomes available for Japanese healthcare institutions."
  • "Echocardiography Core Laboratory Validation of a Novel Vendor-Independent Web-Based Software for the Assessment of Left Ventricular Global Longitudinal Strain".

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Retrieved on: 
Monday, April 17, 2023

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Key Points: 
  • Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.
  • Very positive outcome at one month follow-up of the patient implanted with the Epygon mitral valve.
  • Less than 4% of patients with severe heart mitral insufficiency receive surgery, according to Affluent Medical estimates.
  • It is the only biomimetic cardiac mitral valve in development, mimicking the native mitral valve and physiological blood flow.

Veterinary Dentistry Specialists in Mt. Laurel, NJ, Adds a Veterinary Cardiologist to Team of Board-Certified Specialists in Dentistry and Anesthesia

Retrieved on: 
Monday, April 10, 2023

Laurel, NJ, office of Veterinary Dentistry Specialists (VDS), a veterinary dentistry and oral surgery practice, has added board-certified veterinary cardiologist Megan King, VMD, DACVIM (Cardiology), to its roster of dental and anesthesia specialists.

Key Points: 
  • Laurel, NJ, office of Veterinary Dentistry Specialists (VDS), a veterinary dentistry and oral surgery practice, has added board-certified veterinary cardiologist Megan King, VMD, DACVIM (Cardiology), to its roster of dental and anesthesia specialists.
  • Adding comprehensive outpatient veterinary cardiology services makes VDS the first and only veterinary dentistry and oral surgery practice in the nation with anesthesiology and cardiology specialists available to care for each patient.
  • Cardiology services are also available for pet patients who do not need dentistry services.
  • She then earned Diplomate status by becoming board certified in veterinary cardiology by the American College of Veterinary Internal Medicine.

BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

Retrieved on: 
Wednesday, March 29, 2023

The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.

Key Points: 
  • The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.
  • This year holds the potential for catalysts that could dramatically improve our prospects, timetable, and attractiveness as a business.
  • Following the review, the DSMB indicated that it had no significant safety concerns and recommended that the study continue as designed.
  • After working with distinguished physician leaders, BioCardia expects to complete its formal submission for Japanese approval in the second quarter of 2023.